Chen K, Zheng C, Lv Y, et al
Bottom line on safety: If someone considers peptide therapy, it should be under medical supervision with pre-treatment screening (baseline GH/IGF-I, metabolic panel, glucose), ongoing monitoring, and sourcing from reputable, traceable suppliers under a lawful framework
EL246 is an anti-selectin monoclonal antibody that recognises specific positions on the E and L selectins to inhibit cell adhesion
Medical Supervision: Essential to consult a healthcare provider to tailor the dosage to individual needs
At the cellular level, this effect appears to be mediated through increased purinergic receptor activity, connexin-43 expression, and increased release of pro-inflammatory cytokines
Maintaining healthy lipid metabolism and vascular function*